ASCO GI 2023 | Unanswered questions in gastrointestinal neuroendocrine tumors

Bahar Laderian, MD, Cleveland Clinic, Cleveland, OH, discusses unmet needs in the management of gastrointestinal neuroendocrine tumors. There is currently no definite treatment strategy in second-line settings, where a trial assessing capecitabine with temozolomide versus 177Lu-DOTATATE is currently underway. There is, hence, a need for novel therapies other than everolimus and sunitinib, which both have unfavorable toxicity profiles. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.